2-(5-溴-2-噻吩)-2-氧代乙酸乙酯 | 22098-10-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(5-溴-2-噻吩)-2-氧代乙酸乙酯
• 中文别名: 5-溴噻吩-2-基)(氧代)乙酸乙酯
• 英文名称: ethyl 2-(5-bromothienyl)glyoxalate
• 英文别名: ethyl 2-(5-bromothiophen-2-yl)-2-oxoacetate；(5-bromo-thiophen-2-yl)-oxo-acetic acid ethyl ester；ethyl (5-bromo-thien-2-yl)glyoxylate；ethyl (5-bromo-2-thienyl)glyoxylate；ethyl 2-(5-bromothien-2-yl)-2-oxoacetate
• CAS: 22098-10-8
• 化学式: C₈H₇BrO₃S
• 分子量: 263.112
• InChiKey: PMBGHMBDWGNJJE-UHFFFAOYSA-N

物化性质

• 熔点：
  70-72
• 沸点：
  325.0±27.0 °C(Predicted)
• 密度：
  1.612±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

SDS

Name:	Ethyl 2-(5-bromo-2-thienyl)-2-oxoacetate 97% Material Safety Data Sheet
Synonym:	Ethyl 2-(5-bromothien-2-yl)glyoxylat
CAS:	22098-10-8

Section 1 - Chemical Product MSDS Name:Ethyl 2-(5-bromo-2-thienyl)-2-oxoacetate 97% Material Safety Data Sheet
Synonym:Ethyl 2-(5-bromothien-2-yl)glyoxylat

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
22098-10-8	Ethyl 2-(5-bromo-2-thienyl)-2-oxoaceta	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 22098-10-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow - dark brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 50 - 52 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7BrO3S
Molecular Weight: 263

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 22098-10-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 2-(5-bromo-2-thienyl)-2-oxoacetate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 22098-10-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 22098-10-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 22098-10-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(5-溴-2-噻吩)-2-氧代乙酸乙酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 4-二甲氨基吡啶 、 水 、 potassium acetate 、 三乙酰氧基硼氢化钠 、 potassium carbonate 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 5.5h， 生成 2-(tert-butyldimethylsilyloxy)-2-(5-(5-chloro-4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)thiophen-2-yl)acetic acid
  参考文献：
  名称：

  [EN] PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS
  [FR] COMPOSÉS PYRIMIDINE EN TANT QU'INHIBITEURS DE LA TUBERCULOSE

  摘要：

  本发明涉及化合物II，用作治疗结核病的抑制剂。该发明还提供了制备本发明化合物的方法。

  公开号：

  WO2011019405A1
• 作为产物：
  描述：

  2-溴噻吩 、 草酰氯单乙酯 在 三氯化铝 作用下， 以 硝基甲烷 为溶剂， 以69%的产率得到2-(5-溴-2-噻吩)-2-氧代乙酸乙酯
  参考文献：
  名称：

  取代的噻吩基乙醇酸顺式-3,3,5-三甲基环己酯取代的顺式-3,3,5-三甲基环己基乙醇酸

  摘要：

  将生物等排原理应用于药物环兰地酯（Spasmocyclon®、Natil®）导致了异类酯的产生；两种化合物的药理学测试，如环地平，是非对映异构体的混合物，显示出微弱的钙拮抗作用 1)。

  DOI：

  10.1002/ardp.19893221115

文献信息

• Chromone fungicides
  申请人：Agrevo UK Limited

  公开号：US06034121A1

  公开（公告）日：2000-03-07

  Compounds of the formula ##STR1## where one of Z and Y is CO and the other is C--W--R.sup.2 and the dotted line indicates a double bond is present where necessary to meet valency requirements, W is O, S(O).sub.n, N(R.sup.3), N(R.sup.3)(R.sup.4), N(R.sup.3)O or ON(R.sup.3); R.sup.1 is hydrogen, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, phenyl or heterocyclyl group; R.sup.2, R.sup.3 and R.sup.4, which may be the same or different, are as defined above for R.sup.1, or are acyl, or R.sup.2 and R.sup.3 or R.sup.2 and R.sup.4 or R.sup.3 and R.sup.4 together with the nitrogen or oxygen to which they are attached form an optionally substituted ring which may contain other hetero atoms; each X, which may be the same as or different from any other X, is halogen, CN, NO.sub.2, SF.sub.5, B(OH).sub.2, triakylsilyl or a group E, OE or S(O).sub.n E where E is a group as defined hereinbefore for R.sup.2 or is optionally substituted amino; or two adjacent groups X together with the atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring; n is 0, 1 or 2; and p is 0 to 4 have fungicidal activity. Many of the compounds are novel.

  式为##STR1##的化合物，其中Z和Y中的一个是CO，另一个是C--W--R.sup.2，虚线表示必要时存在双键以满足化合价要求，W是O，S(O).sub.n，N(R.sup.3)，N(R.sup.3)(R.sup.4)，N(R.sup.3)O或ON(R.sup.3)；R.sup.1是氢，或者是可选择取代的烷基，烯基，炔基，环烷基，苯基或杂环基；R.sup.2，R.sup.3和R.sup.4，可以相同也可以不同，如上所定义的R.sup.1，或者是酰基，或者R.sup.2和R.sup.3或R.sup.2和R.sup.4或R.sup.3和R.sup.4与它们连接的氮或氧一起形成一个可选择取代的环，该环可能含有其他杂原子；每个X，可以与任何其他X相同或不同，是卤素，CN，NO.sub.2，SF.sub.5，B(OH).sub.2，三烷基硅基或者是一个E，OE或S(O).sub.n E基团，其中E是如上所定义的R.sup.2或者是可选择取代的氨基；或者两个相邻的X基团与它们连接的原子一起形成一个可选择取代的碳环或杂环；n为0，1或2；p为0到4具有杀真菌活性。其中许多化合物是新颖的。
• Synthesis and receptor affinities of new 3‐quinuclidinyl α‐heteroaryl‐α‐aryl‐α‐hydroxyacetates
  作者：Victor I. Cohen、Raymond E. Gibson、Linda H. Fan、Rosanna de la Cruz、Miriam S. Gitler、Erin Hariman、Richard C. Reba

  DOI：10.1002/jps.2600810405

  日期：1992.4

  analogues of 3‐quinuclidinyl benzilate were prepared in which one phenyl ring was substituted by a heterocycle; a bromine was included on either the remaining phenyl or the heterocycle to provide information relating to the affinity of potential radiohalogenated derivatives. Their affinities for the muscarinic cholinergic receptor were determined. Replacing a phenyl ring with either the 2‐ or 3‐furyl moiety

  摘要制备了5-苯甲酸3-奎宁环烷基酯的5个类似物，其中一个苯环被杂环取代。在剩余的苯基或杂环上包括一个溴，以提供与潜在的放射性卤代衍生物的亲和力有关的信息。确定了它们对毒蕈碱胆碱能受体的亲和力。与3-奎宁环烷基4-溴苯甲酸酯相比，用2-或3-呋喃基部分或2-或3-噻吩基部分取代苯环不会显着改变对毒蕈碱受体的亲和力。
• QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS
  申请人：Gai Yonghua

  公开号：US20080267918A1

  公开（公告）日：2008-10-30

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I化合物，或其药用可接受的盐、酯或前药： 其抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含前述化合物的药物组合物，用于给患有HCV感染的对象服用。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体中的HCV感染的方法。
• [EN] QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] COMPOSÉS CONTENANT DE LA QUINOXALINE EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2009064975A1

  公开（公告）日：2009-05-22

  The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了抑制丝氨酸蛋白酶活性的I和II公式化合物，或其药物可接受的盐、酯或前药，尤其是抑制丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也用作抗病毒剂。本发明进一步涉及包含前述化合物的药物组合物，用于给患有HCV感染的主体进行管理。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体中的HCV感染的方法。
• [EN] NEW QUINUCLIDINE AMIDE DERIVATIVES<br/>[FR] DERIVES DE QUINUCLIDINE AMIDE
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2004005285A1

  公开（公告）日：2004-01-15

  New quinuclidine amide derivatives having the chemical structure of general formula (I) and pharmaceutically acceptable salts thereof including quaternary salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions 10 comprising them and their use in therapy as antagonists of M3 muscarinic receptors.

  新的喹啉啉酰胺衍生物具有通式（I）的化学结构，以及其药学上可接受的盐，包括通式（II）的季铵盐；以及它们的制备方法，包括它们的药物组合物和作为M3胆碱能受体拮抗剂在治疗中的用途。